Electrochemotherapy of skin metastases from malignant melanoma: a PRISMA-compliant systematic review

Martina Ferioli1 · Valentina Lancellotta2 · Anna Myriam Perrone3 · Alessandra Arcelli1 · Andrea Galuppi1 · Lidia Strigari4 · Milly Buwenge1 · Francesca De Terlizzi5 · Silvia Cammelli1 · Roberto Iezzi6,7,8 · Pierandrea De Iaco3 · Luca Tagliaferri2 · Alessio G. Morganti1

Received: 19 November 2021 / Accepted: 1 July 2022 / Published online: 22 July 2022
© The Author(s) 2022

Abstract
The main treatment of MM metastases are systemic therapies, surgery, limb perfusion, and intralesional talimogene laherparepvec. Electrochemotherapy (ECT) is potentially useful also due to the high response rates recorded in cancers of any histology. No randomized studies comparing ECT with other local therapies have been published on this topic. We analyzed the available evidence on efficacy and toxicity of ECT in this setting. PubMed, Scopus, and Cochrane databases were screened for paper about ECT on MM skin metastases. Data about tumor response, mainly in terms of overall response rate (ORR), toxicity (both for ECT alone and in combination with systemic treatments), local control (LC), and overall survival (OS) were collected. The methodological quality was assessed using a 20-item validated quality appraisal tool for case series. Overall, 18 studies were included in our analysis. In studies reporting “per patient” tumor response the pooled complete response (CR) was 35.7% (95%CI 26.0–46.0%), and the pooled ORR was 80.6% (95%CI 68.7–90.1%). Regarding “per lesion” response, the pooled CR was 53.5% (95%CI 42.1–64.7%) and the pooled ORR was 77.0% (95%CI 56.0–92.6%). One-year LC rate was 80%, and 1-year OS was 67–86.2%. Pain (24.2–92.0%) and erythema (16.6–42.0%) were the most frequent toxicities. Two studies reported 29.2% and 41.6% incidence of necrosis. ECT is effective in terms of tumor response and tolerated in patients with skin metastases from MM, albeit with a wide variability of reported results. Therefore, prospective trials in this setting are warranted.

Keywords Electrochemotherapy · Melanoma · Skin metastases · Systematic review · Local control

Introduction
The incidence of malignant melanoma (MM) in Europe is 150,627 new cases per year with a mortality of 26,360 deaths per year [1]. Around 2–20% of patients with advanced MM...
develop skin and/or subcutaneous metastases [2]. The main available treatment options of MM metastases are systemic therapies, surgery, limb perfusion, and intraläsional talimogene laherparepvec (T-VEC) [3, 4].

Electrochemotherapy (ECT) is a well-established local therapy of primary and metastatic superficial tumors, whose efficacy was demonstrated by several clinical studies showing approximately 80% overall response rates (ORR) [5]. In addition, international operating procedures are available for ECT [5, 6]. Skin metastases with any histologic type can be treated with ECT. In fact, ECT acts through transmission of electric pulses by creating transient cell membrane pores increasing drugs concentration and cytotoxic effect at intracellular level. Some clinical trials showed that bleomycin (BLM) and cisplatin (CDDP) are the most effective chemotherapy drugs when combined with electrical pulses ECT [6, 7]. Therefore, both are used during ECT. Moreover, electrical pulses lead to vasoconstriction thus resulting in drug trapping (“vascular lock”) and vascular disrupting effect [8]. Nowadays, ECT is mainly applied as a palliative treatment in order to improve patients’ quality of life, although in some cases it can allow for a prolonged local tumor control. Furthermore, ECT is increasingly being tested and used also in combination with systemic or other local treatments.

Considering the efficacy of ECT in other skin cancers [5, 9, 10], and the potential advantage of the hemostatic effect produced by the vascular lock in hemorrhagic lesions, some studies tested ECT in cutaneous MM metastases [11, 12]. However, no randomized study comparing ECT with other local therapies have been published on this topic.

Based on this background, the aim of this systematic review on melanoma skin metastases is to analyze the available evidence on efficacy and toxicity of ECT on skin metastases from MM.

Materials and methods

Before starting the literature screening, the review was registered on the PROSPERO international register on January 4, 2021 [13]. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were applied in the review process [14]. Primary endpoints were tumor response, mainly in terms of ORR, and toxicity of ECT alone or combined with other therapies. Secondary endpoints were local control (LC) and overall survival (OS). PubMed, Scopus, and Cochrane databases were screened by the authors and the reference lists of the included studies were also checked. The search strategy was as follows: ((electroporation[Title/Abstract]) OR (electrochemotherapy[Title/Abstract])) AND (melanoma[Title/Abstract]). Retrospective and prospective studies, case series, and clinical trials in the setting of MM skin metastases were included. Instead, we excluded case reports, papers reporting duplicate data, study protocols, papers where tumor response or toxicity were not reported or with tumor response and toxicity not reported separately from other tumors, systematic or narrative reviews, meta-analyses, letter-commentaries, editorials, planning studies, imaging studies, surveys, guidelines, recommendations and papers published not in English.

Study selection

Two authors (MF, AA) independently assessed the literature articles, selected papers at title/abstract level, and removed duplicate. The full text of potentially eligible articles was analyzed. In case of disagreement, a third author (AMP) was involved in the final decision.

Data extraction

Data were collected in an excel spreadsheet. The extracted data included: ECT characteristics (drug, route of administration, number of treatments, number and size of treated metastases), previous or concurrent treatments and their characteristics, tumor response after first ECT course in term of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) and ORR, and toxicity. Two authors (MF, AA) independently extracted data and disagreement between individual judgments was solved by a third author (AMP).

Quality assessment

Methodological quality was assessed using a 20-item validated quality appraisal tool for case series [15], by two authors (AG, MB), independently. Disagreements were solved by a third author (SC). Quality judgments for each item had a binary determination (“yes” or “not/not reported”) regarding study objectives, clear population description, interventions and co-interventions, outcome measures, statistical analysis, results, conclusions, and competing interests. A study with at least 15 “yes” responses was considered of acceptable quality.

Statistical analysis

Statistical analysis was carried out using the MedCalc statistical software (version 15.2.2, MedCalc Software bvba, Ostend, Belgium). All tests were two-sided. The I2 statistic was used to quantify statistical heterogeneity (high heterogeneity level: > 50%). The latter was tried out with the Q2 test. Statistical significance was considered as p < 0.05, except when investigating heterogeneity among studies (p < 0.1). In case of heterogeneity among selected studies, rates and
proportions were pooled using a random-effects model. A fixed-effect model was used in other cases. The dependent variables were modeled on the logit (log-odds) scale, converted back to percentages, and then presented as point estimates and 95% CI.

Results

The search results are shown in the PRISMA flow-chart (Fig. 1). After duplicate removing, 983 articles were evaluated, and 24 full-text articles were selected. Six of them were excluded from the final analysis for the following reasons: one letter to editor, one case report, one with no data on tumor response, one without separated data on ECT, one reporting on the same patients population of a more recent study by the same authors, and one reporting on primary MM. Seven studies had a retrospective design [16–22], ten were prospective [11, 12, 23–30] and one was a prospective-prospective analysis [31]. Six studies were published before ESOPE guidelines were issued in 2006 [16–18, 23, 24, 26]. Studies’ characteristics are described in Tables 1 and 2.

Patients and tumors characteristics

Overall, as showed in Tables 1 and 529 patients were treated with ECT on 2987 skin MM metastases. However, five papers did not report the number of treated metastases [19, 20, 22, 29, 31]. Most lesions were in the trunk and extremities. The size of the treated metastases was reported heterogeneously: some authors reported the volume [11, 16, 23, 24], others the diameter [12, 18, 19, 21, 25–30], while four papers did not describe this data [17, 20, 22, 31]. Looking at the diameter, the range was 2–260 mm. Most articles also reported the number of lesions per patient, with figures
| Authors/year | Study design | No. patients treated/ evaluable | No. lesions treated/ evaluable | Lesions per patient | Drug | Route | Electrode | Anesthesia | No ECT courses | Lesions size | Previous therapies | Concurrent therapies | Site of lesions |
|--------------|--------------|-------------------------------|-------------------------------|-------------------|------|-------|----------|-----------|----------------|-------------|------------------|-------------------|---------------|
| Rudolf Z. et al., 1995 | Retrospective | 2/2 | 24/24 | Range 1–13 | BLM | IV | Long needles | LA | 1–3 | Range 16–2915 | Surgery, CHT, IFN, RT | None | Extremities |
| Glass LF. et al., 1996 | Retrospective | 5/5 | 23/23 | NR | BLM | IT | Plate/hexagonal | LA | 1 | NR | NR | NR | NR |
| Rols MP. et al., 2000 | Retrospective | 4/4 | 55/55 | Range 10–22 | BLM | IV | Plate | GA/LR | 1 | Range 2–35 | Surgery, CHT, RT | None | Trunk, extremities |
| Sersa G. et al., 2000 | Phase I-II | 9/9 | 27/27 | NR | CDDP | IV | Linear | LA | 1 | Mean 1010 | NR | Vinblastine, lomustine, IFN alfa | NR |
| Sersa G. et al., 2000 | Phase II | 10/10 | 133 | Range 1–44 | CDDP | IT | Linear | LA | 1 | Median 61 (range 2–39,270) | surgery, CHT, IFN | None | NR |
| Byrne CM. et al., 2005 | Phase II randomized | 19/15 | 46/36 | Range 2–4 | BLM | IT | Linear | LA | 1 | Range 3–50 | Surgery, ILP | None | Extremities abdomen, neck |
| Gaudy C. et al., 2006 | Randomized controlled | 12/10 | 54/40 | Range 2–12 | BLM | IT | Hexagonal | LA | 1 | Median 10 (range 3–26) | NR | CHT in 8 pts (66%) | NR |
| Quaglino C. et al., 2008 | Prospective | 14/14 | 233/233 | Mean 10 | BLM | IV | Plate/hexagonal/linear | GA | 1–3 | Range 2–75 | CHT, ILP | NR | Extremities |
| Kis E. et al., 2011 | Retrospective | 9/9 | 158/158 | Mean 17.5 (range 1–62) | BLM | IV | Hexagonal/linear | GA | 1 | Mean 1.47 (0.5–5.6 cm) | Surgery, CHT, IFN, RT | None | Trunk, extremities |
| Campana LG. et al., 2012 | Prospective | 85/85 | 894/894 | Median 11 (1–50) | BLM | IV-IT | NR | LA-GAS | 1–6 (median 3 courses) | Median 24 (range 3–75) | CHT, IFN, RT, ILP | None | Trunk, extremities |
| Ricotti F. et al., 2014 | Prospective | 30/30 | 654/654 | Median 21.8 (range 4–54) | BLM | IV | NR | GA | 1–2 | 10 cm² | NR | None | NR |
| Authors/ year | Study design | No. patients treated/ evaluable | No lesions treated/ evaluable | Lesions per patient | Drug | Route | Electrode | Anesthesia | No ECT courses | Lesions size | Previous therapies | Concurrent therapies | Site of lesions |
|--------------|--------------|-------------------------------|-------------------------------|---------------------|------|-------|----------|------------|---------------|-------------|---------------------|---------------------|----------------|
| Mir-Bonafè JM. et al., 2015 | Retrospective – prospective | 31/31 | NR | NR | BLM | IV | Hexagonal | NR | 1–3 | NR | surgery, CHT, ILP | None | HN,trunk, extremities |
| Caracò C. et al., 2015 | Retrospective | 89/89 | NR | NR | BLM | IV | Plate/hexagonal | GA-LR | 1–6 | median 12 (range 2–35)\(^b\) | surgery | None | HN,trunk, extremities |
| Mozzillo N. et al., 2015 | Retrospective | 15/15 | NR | NR | BLM | IV | NR | NR | NR | NR | CHT | Ipilimumab | Skin |
| Hribernik A. et al., 2016 | Retrospective | 5/5 | 111/111 | Range 1–80 | BLM-CDDP | IV-IT | Plate | NR | 1 | Median 1.5 cm (range 0.8–3)\(^b\) | Surgery, IFN | None | Trunk, extremities |
| Hepp M. et al., 2016 | Retrospective | 33/33 | NR | NR | BLM | IV-IT | Hexagonal/linear | GA-LA | NR | NR | CHT, immunotherap\(^g\) within 4 weeks | HN,trunk, extremities |
| Tomassini GM. et al., 2016 | Prospective | 6/6 | 69/6 | NR | BLM | IV | Hexagonal/linear/finger | S | 1 | Range 2–260\(^b\) | NR | NR | Trunk, extremities |
| Kunte C. et al., 2017 | Prospective | 151/114 | 506/394 | Median 3 (range 1–6) | BLM | IV-IT | Plate/hexagonal/linear | GA-LA | 1–4 | Median 9 (range <5–>30)\(^b\) | Surgery, CHT, RT, ILP | NR | HN,trunk, extremities |

BLM Bleomycin, CDDP cisplatin, CHT chemotherapy, ECT Electrochemotherapy, EP electroporation, IFN interferon, ILP isolated limb perfusion, IT intratumoral; IV intravenous; LA local anesthesia, LR loco-regional anesthesia, NR not reported, RT radiotherapy, GA general anesthesia, S sedation

\(^a\)Lesions dimension reported as volume (mm\(^3\) unless otherwise reported)
\(^b\)Lesions dimension reported as diameter (mm unless otherwise reported)
\(^c\)82 lesions treated with ECT, 27 with CDDP, 2 with EP, and 22 were controls
\(^d\)18 lesions treated with ECT vs. 18 treated with BLM alone
\(^e\)30 lesions treated with ECT and 24 with BLM alone
\(^f\)9 target lesions and the other considered “no target lesions”
\(^g\)Ipilimumab-pembrolizumab-nivolumab
Table 2 Tumor response and toxicity

| Author/year          | Time of response evaluation | Follow-up duration, months-median (range) | CR (%) | PR (%) | SD (%) | PD (%) | ORR (%) | Response evaluation (lesions or patients) | Scale | Toxicity                                                                 |
|----------------------|----------------------------|------------------------------------------|---------|--------|--------|--------|--------|-------------------------------------------|-------|--------------------------------------------------------------------------|
| Rudolf Z. et al., 1995 | 4 weeks                    | NR                                       | 92      | 0      | 4      | 4      | 92     | Lesions                                   | WHO   | Erythema, muscle spasm, local pain                                       |
| Glass L.F. et al., 1996 | 12 weeks                   | NR                                       | 78      | 17     | 4      | 0      | 96     | Lesions                                   | NR    | Erythema and edema                                                        |
| Rols MP. et al., 2000  | NR                         | NR                                       | 9       | 81     | NR     | NR     | 90     | Lesions                                   | NR    | Erythema, edema, superficial necrosis, hyperthermia,                     |
| Sersa G. et al., 2000  | 4 weeks                    | NR                                       | 11      | 37     | 41     | 11     | 48     | Lesions                                   | WHO   | Erythema                                                                                |
| Sersa G. et al., 2000  | 4 weeks                    | 35 (5–124)                               | 68      | 10     | 15     | 7      | 78     | Lesions                                   | WHO   | Erythema and edema                                                        |
| Byrne CM. et al., 2005 | 12 weeks                   | M: 21                                    | 72      | 5      | 18     | 5      | 77     | Lesions                                   | WHO   | Pain, muscle spasm                                                        |
| Gaudy C. et al., 2006  | 4 weeks/12 weeks           | 24                                       | 74–66   | 13–18  | NR     | NR     | 87–82 | Lesions                                   | WHO   | Pain 75%, muscle spasm 25%, erythema 16.6%, necrosis 41.6%               |
| Quaglino C. et al., 2008 | 8 weeks                   | 21                                       | 50/58   | 43/34  | 7/8    | 0      | 93/92 | Lesions/patients                          | WHO   | Erythema 21.4%, pain 0%                                                  |
| Kis E. et al., 2011   | 8 weeks                    | 195 days (60–358)                        | 23      | 39     | 30     | 8      | 62     | Lesions                                   | WHO   | Erythema, edema                                                          |
| Campagna LG. et al., 2012 | 4 weeks                   | 26 (6–47)                               | 44/48   | 0/46   | 53/4  | 1/2    | 44/94 | Lesions/patients                          | RECIST| Pain 92%, syncope 4.7%, nausea 9.4%, fever 4.7%, skin G3 18%             |
| Ricotti F. et al., 2014 | 4 weeks                    | 20                                       | 67.3/70 | 32.7/80 | 100/100 | Lesions/patients                          | WHO   | NR                                                                 |
| Mir-Bonafè JM. et al., 2015 | 4 weeks                   | NR                                       | 23      | 49     | 0      | 28     | 72     | Patients                                  | RECIST| Ulceration and infection (25.8%), pain, edema, erythema, nausea, vomiting |
| Caracò C. et al., 2015 | 12 weeks                   | 27.5 (6–67)                              | 48.3    | 38.2   |        |        | 67.5   | Patients                                   | WHO   | Pain 37%, myalgia 13.5%, necrosis 29.2%                                   |
| Mozzillo N. et al., 2015 | 4 weeks                    | NR                                       | 27      | 40     | 0      | 33     | 67     | Patients                                   | WHO   | Pruritus 80%                                                              |
| Hribnik A. et al., 2016 | 4 weeks                    | NR                                       | 85      |        |        |        |        | Lesion                                    | WHO   | None                                                                 |
| Heupt M. et al., 2016  | Median 12 weeks (range 4–32)| 9                                        | 15.2    | 51.5   | 9.1    | 24.2   | 66.7   | Patients                                   | RECIST| Ulceration 45.5%, erythema 42.4%, infection 30.3%, pain 24.2%, nausea 9.9% (G3) |
| Tomassini GM. et al., 2016 | 8 weeks                   | NR                                       | 33.3    | 0.0    | 44.4   | 22.3   | 33.3   | Lesions                                   | RECIST| NR                                                                 |
| Kunte C. et al., 2017  | 8 weeks                    | 116 days                                 | 58/48   | 20/25  | 20/26  | 2/3    | 78/74 | Lesions/patients                          | RECIST| Skin toxicity 50% (G3 in 2 pts), nausea 4%, lymphedema 4%, flu like symptoms 5%, pain 39% |

CR complete response, M mean, NR not reported, ORR objective response rate, PD progression disease, PR partial response, RECIST response evaluation criteria in solid tumors, SD stable disease, WHO World Health Organization

*78% after second course in previous PR lesions

*After first course, after the second course the CR was 89% of lesions

*Response evaluated on the nine target lesions; all non-target lesions were classified as SD
ranging between one and 80 lesions. Furthermore, before ECT, most patients included in the analyzed papers underwent chemotherapy, surgery and interferon. Radiotherapy was reported as previous treatment in six studies [12, 16, 18, 22, 28, 30] with available data on the number of previously irradiated patients on the same area of ECT. One paper also described the toxicity in this patients subgroup [12].

**Treatment characteristics**

ECT was based on BLM in 15 studies [11, 12, 16–20, 22, 25–31], on CDDP in two studies [23, 24] and on both drugs in one study [21], with intravenous [11, 12, 16, 18–22, 24, 27–31] or intratumoral [12, 17, 21–23, 25, 26, 30] administration. The used electrodes were mainly linear [22–25, 27–30], hexagonal [17, 19, 22, 26–31] and plate [17–19, 21, 27, 30], while anesthesia was mostly local [12, 16, 17, 22–26, 30] for general [11, 12, 18, 19, 22, 27, 28, 30]. Overall, ECT courses ranged from one to six. Four authors reported that ECT was concurrent to chemotherapy [24, 26] or immunotherapy [20, 22]. In the others papers the lack of concurrent therapies was declared [11, 12, 16, 18, 19, 21, 23, 25, 28, 31] or this information was not available [17, 27, 29, 30].

**Outcomes**

**Local control**

The clinical response was reported in terms of local tumor response (CR, PR, SD, PD, ORR) on a “per lesion” [16–18, 21, 23–26, 28, 29] or a “per patient” basis [19, 20, 22, 31] or both [11, 12, 27, 30], as shown in Table 2. In studies reporting “per lesion” tumor response, the ORR ranged between 33.3 and 100% (pooled rate: 77.0%; 95%CI 56.0–92.6; Fig. 2a), and the CR between 9 and 92% (pooled rate: 53.5%; 95%CI 42.1–64.7; Fig. 2b). Moreover, the “per patient” ORR ranged between 66.7 and 100% (pooled rate: 80.6%; 95%CI 68.7–90.1; Fig. 3a) and the CR between 15.2 and 50% (pooled rate: 35.7%; 95%CI 26.0–46.0; Fig. 3b). The timing of response evaluation after ECT was heterogeneous among studies but most assessments were performed four weeks after the first ECT course [11, 12, 16, 20, 21, 23, 24, 26, 31]. The Response Evaluation Criteria in Solid Tumors (RECIST) scale and the World Health Organization (WHO) criteria were used in five [12, 22, 29–31] and 11 [11, 16, 19–21, 23–28] papers, respectively, while two studies did not report the tumor response scoring system [17, 18]. Actuarial LC was reported in four studies [11, 12, 27, 30]. Three papers reported 72–87% 2-year LC, with 80% 1-year LC in one paper, and one study reported 86% LC rate after 200-days.

**Survival outcomes**

Other clinical outcomes were reported in some study: three papers analyzed OS and reported 67–86.2% 1-year OS [20, 30] and 15 months OS in patients treated with ECT plus concurrent anti-Programmed Death 1 (PD1) immunotherapy [22], respectively. PFS was reported by two authors [12, 22]. Campana et al. reported 87% 2-year local PFS [12] while Hepp et al. reported 2.5 months median PFS [22]. Melanoma specific survival was reported by Kunte et al. as 74% 1-year rate [30]. Only ten studies reported the follow-up duration [11, 12, 19, 22, 23, 25–28, 30], ranging between 116 days and 35 months.

**Internal comparisons**

Three studies compared ECT versus BLM- or CDDP-based intravenous chemotherapy alone [24–26] reporting significantly higher CR rates after ECT. Finally, two authors reported higher LC rates in smallest lesions, especially those < 3 cm [12, 30]. Despite ECT was mostly used as palliative treatment, only one study reported the results in terms of symptoms relief [29], showing a reduction in bleeding and pain, while no paper analyzed the Quality of Life.

**Toxicity**

Seven papers reported only which toxicity was the most frequent [16–18, 23–25, 28] while the others reported the specific rates [12, 19, 20, 22, 26, 27, 30, 31]. Pain and erythema were the most common side effects. More specifically, pain was reported by 24.2–92.0% of patients and erythema was recorded in 16.6–42.0% of subjects. Two studies [19, 26] reported a non-negligible incidence of necrosis (41.6% and 29.2%, respectively). Finally, some authors reported variable rates of infections, ulcerations, muscle spasms, and nausea, as shown in Table 2.

**Quality assessment**

Only seven studies were of acceptable quality after evaluation with the case series quality appraisal checklist [12, 23, 25–28, 30]. In fact, all authors reported the number of patients but four studies did not report the number of treated lesions [19, 20, 22, 31]. Four studies did not report the metastases size [17, 20, 22, 31] and the lesions site was not reported in five studies [11, 17, 23, 24, 26]. Previous therapies were described by most authors [12, 16, 18–23, 25, 27, 28, 30, 31], but often as general information while only few authors specifically reported previous local treatments on ECT-treated lesions [12, 16, 18, 22, 28, 30]. Finally,
the tumor response was reported on a “per lesion” or “per patient” basis by most authors with only four papers reporting both [11, 12, 27, 30].

Discussion

In our systematic review on ECT in skin MM we recorded 53.5% and 77% pooled complete and overall response rates on a per lesion basis, respectively. Most frequently reported toxicities were pain and erythema which were reported as mild in most patients. Therefore, based on the available evidence, ECT can be considered well tolerated and effective in terms of tumor response in this setting, albeit with a wide variability of the reported results [9, 10, 32, 33]. Finally, the pooled rates reported in this analysis can serve as a benchmark for further studies aimed at improving current outcomes by optimizing treatment techniques and patient selection, as well as improving treatments combinations.

Some authors suggested an immunostimulating effect of ECT [34, 35], and therefore a possible synergistic effect of ECT and immunotherapy [3]. Therefore, considering the efficacy of immunotherapy in MM, some studies included
in our analysis tested this combined modality treatment [20, 22].

Nevertheless, in our analysis we did not record improved results in series of combined ECT plus immunotherapy [20–22]. In fact, the ORR rate after ECT alone was 67.5–100.0% [11, 12, 19, 27, 30, 31] while after ECT plus immunotherapy was 66.7–67.0% [20, 22]. It should be noted that in some series on combined modality treatment the 1-year OS rates were relatively high (86.2%) [20]. However, a comparison with ECT alone in terms of OS was not feasible being this endpoint not reported in most of the latter papers [11, 12, 19, 27, 31]. Comparing immunotherapy alone or combined with local treatments, Theurich et al. reported the outcomes after Ipilimumab versus Ipilimumab plus local therapies (radiotherapy, ECT). The addition of local treatment to ipilimumab significantly prolonged OS (median: 93 versus 42 weeks, p: 0.0028) [36]. However, only four out of 45 enrolled patients were treated with ECT. Finally, Campana et al., in their recent retrospective analysis, showed how Pembrolizumab combined to ECT in melanoma patients (stage IIIC-IV) improves 1-year PFS and OS (p = 0.034 and p = 0.006, respectively) [37].

Fig. 3  

- **a** Forest plot of the overall response rates reported on a per patient basis.  
- **b** Forest plot of the complete response rates reported on a per patient basis.
In our analysis no series reported on combined RT plus ECT. However, Kunte et al. reported worse LC rates in previously irradiated metastases [30].

Among studies reporting tumor response on a “per lesion” basis, we recorded a wide variability both in terms of CR (9.0–92.0%) and ORR (33.3–100.0%). Rols et al. [18] and Rudolf et al. [16] reported the lowest and the highest CR rate, respectively. Both authors treated few patients (four and two patients with 55 and 24 lesions, respectively) but the first used a plate electrode, usually able to treat only the exophytic region of the skin lesions, while the other used the long needles electrodes, able to better treat the whole tumor volume. In terms of ORR rate, Tomassini et al. and Ricotti et al. reported 33.3% [29] and 100.0% rates [11], respectively. Beyond the different parameters used to evaluate the lesions size in the two studies (diameter vs. area), it can be observed that the maximum tumor size in the first series were clearly larger than the second one (260 mm vs. 10 cm²) and this might explain the different response rates.

Smaller differences were recorded regarding the response rates assessed on a “per patient” basis. In fact, the CR rates ranged between 15.2% and 50.0% and the ORR rates between 66.7% and 100.0%. Heppt et al. reported the worst CR and ORR rates, but they did not describe either the lesions number or the tumors size. Therefore, we cannot assess whether the poor local efficacy is attributable to these factors. However, it can be noted that nearly 30% of MM metastases were in previously irradiated areas and this may have had a negative effect on ECT efficacy due to reduced tissue perfusion and its consequences on the electrical pulses transmission [22]. Furthermore, the drug administration route was both intravenous and intratumoral. Instead, the authors who reported the best response rates [11, 27] used only the intravenous route, which is known to be more effective especially in larger lesions [5].

Overall, pain and erythema were the most common toxicities. Unfortunately, different scoring systems and lack of information on incidence rates make it difficult to assess frequency, severity, and predictors of adverse events in many studies. However, it should be noted that necrosis and ulceration were more frequent in patients treated with hexagonal electrodes [22, 26, 31] and in subjects undergoing concurrent chemotherapy [26] or immunotherapy [22]. Since the hexagonal electrode can provide a higher number of electrical pulses and with a higher voltage, compared to other electrodes, it could have favored ulceration and pain [5].

As previously mentioned, several treatment options are now available for MM metastases. Therefore, a comparison of the results of the latter with those of the ECT would be useful.

The ORR was 10–20% using Dacarbazine-based therapy in patients with metastatic MM, a figure lower compared to the rates recorded after ECT [38]. Similarly, a phase II study on metastatic MM treated with T-VEC, the first and only oncolytic virus approved by the FDA for the treatment of MM, reported 26% ORR, still lower than ECT results [39]. However, results from phase II and III clinical trials as well as real world data showed 26.4% [40], 39%, and 18% [41] ORR, CR, and PR rates after T-VEC therapy, respectively, which appears to be able to stimulate local and systemic immune responses similar to ECT.

It is difficult to identify studies separately reporting the response of skin lesions to immunotherapy, as treated patients often have multi-organ metastases. However, it can be observed that in the CA184-007, CA184-008, and CA184-022 trials the ORR was 40% [42]. Finally, in a phase III trial based on combined Ipilimumab plus Dacarbazine, the ORR was 50% [43]. Therefore, it would be interesting to analyse immunotherapy efficacy in patients affected only by cutaneous metastases. Regarding the comparison between ECT and other local therapies, Moreno-Ramirez et al. [44], in their review on limb perfusion of in-transit MM lesions, reported 90% ORR. These results are similar to those of ECT. However, it should be noted that limb perfusion has site limitations being this treatment mainly directed to metastases in the extremities. Byers et al. [45] reported on in-transit MM metastases treated with intralesional therapy (mainly IL-2). The ORR was 80.5%, again similar to ECT.

Therefore, the comparison among our analysis and available literature data shows that ECT local response rates are superior or at least like those of other treatments, without site limitations as in the case of limb perfusion.

In terms of predictors of ORR after ECT, we compared, based on previous irradiation, the studies included in our review in terms of tumor response. In papers including [12, 22, 28, 30] or not including [19–21, 23, 24, 27, 31] previously irradiated patients, the ORR was 44–78% and 67–93%, respectively, suggesting a negative impact of radiotherapy delivered prior to ECT. Furthermore, Kunte et al. [30] recorded an independent negative impact, on multivariate analysis, of prior irradiation on tumor response. Finally, another analysis, however also including patients with non-melanoma tumors, confirmed the lower CR rate in patients with previous radiotherapy (59% versus 71%) [33].

Our analysis has some limitations: eight studies were retrospective [16–22, 31], ECT was based on different drugs, with different doses and routes of administration, the number of lesions and patients was reported in different ways, the tumor size was assessed and reported based on various parameters, five studies did not report previous therapies [11, 17, 24, 26, 29], data on previous radiotherapy was largely missing, and toxicity was described only narratively in most studies [16–18, 23–25, 28]. Moreover, after quality assessment, less than half of the studies were rated as sufficient. Furthermore, papers published prior to the ESOPE guidelines, when ECT was still considered an experimental
treatment, were also included in the analysis [16–18, 23, 24, 26]. However, we chose to avoid chronological limitations in the inclusion criteria in order to provide the broadest overview of the available evidence. Finally, the Quality of Life was not analyzed, despite the palliative treatment setting.

However, our results are confirmed by the findings of a very recent publication by Petrelli et al. [46], who analyzed the available publications in order to evaluate ORR, LC, and OS after ECT in cutaneous MM. The results of their report are very similar to the findings of our analysis. Indeed, ORR, 2-year LC, and 1-year OS were 77.0% and 77.6%, 72–87% and 67–86%, and 67–89% and 67–89% in our and in Petrelli’s et al. analyses, respectively. Therefore the two review are in agreement in suggesting the local efficacy and long-lasting LC after ECT in this setting.

Conclusions

The results of our analysis suggest that ECT may be considered a treatment option in patients with MM skin metastases. Considering the low grade of available evidence and the need to individualize treatment, especially in the metastatic setting, these patients should ideally be managed by multidisciplinary teams including dermatologists, medical oncologists, and radiation oncologists.

However, considering the promising local response rates, further studies on ECT in this setting are warranted. These trials should aim at: (i) careful assessment of long-term results, both in terms of local control and side effects; (ii) evaluation of the impact of ECT on symptom relief and quality of life; (iii) definition of the best combinations with systemic therapies, in particular with immunotherapy, both in terms of drugs or drug combinations and in terms of timing of the therapeutic sequence.

Author contributions Conception and design: all authors. Literature search: MF, AA and AMP. Analysis and interpretation of data: MF, AMP, AA, FDT, PDI & AGM. Manuscript writing: all authors. Approval of final article: all authors.

Funding Open access funding provided by Alma Mater Studiorum - Università di Bologna within the CRUI-CARE Agreement.

Data availability All data analysed during this study are included in this published article.

Declarations

Competing interest F.D.T. is an employee at IGEA. Two authors (A.G.M. and P.D.I) has received funding from IGEA. All other authors declare that they have no potential conflict of interest in relation to the study in this paper.

Research involving human participants and/or animals Not applicable.

Informed consent Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. GLOBOCAN (2020) Cancer Incidence and Mortality Worldwide: IARC CancerBase. Lyon, France: International Agency for Research on Cancer; http://globocan.iarc.fr. Accessed on 13 Sept 2021
2. Savoia P, Fava P, Nardò T, Osella-Abate S, Quaglino P, Bernengo MG (2009) Skin metastases of malignant melanoma: a clinical and prognostic survey. Melanoma Res 19(5):321–326
3. Goggins CA, Khachemoune A (2019) The use of electrochemotherapy in combination with immunotherapy in the treatment of metastatic melanoma: a focused review. Int J Dermatol 58(8):865–870
4. NCCNguidelines (2021) https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed 13
5. Gehl J, Sersa G, Matthiessen LW, Muir T, Soden D, Occhini A, Quaglino P, Curatolo P, Campana LG, Kunte C, Clover AJP, Bertino G, Farrigha V, Odili J, Dahlstrom K, Benazzo M, Mir LM (2018) Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 57(7):874–882
6. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M et al (2006) Electrochemotherapy—an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 4(11):3–13
7. Morley J, Grocott P, Purruss E, Murrells T (2019) Electrochemotherapy for the palliative management of cutaneous metastases: a systematic review and meta-analysis. Eur J Surg Oncol 45(12):2257–2267
8. Jarm T, Cemazar M, Miklavcic D, Sersa G (2010) Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 10(5):729–746
9. Ferioli M, Galuppi A, Buwenge M, Cammelli S, Perrone AM, Macchia G, Deodato F, Cilla S, Zamagni A, De Terlizzi F, Tagliaferri L, De Iaco P, Morganti AG (2021) Electrochemotherapy in Kaposi sarcoma: a systematic review. Mol Clin Oncol 14(4):1–5
10. Ferioli M, Perrone AM, Buwenge M, Arcelli A, Zamagni A, Macchia G, Deodato F, Cilla S, Tagliaferri L, De Terlizzi F, De Iaco P, Zamagni C, Morganti AG (2021) Electrochemotherapy of skin metastases from breast cancer: a systematic review. Clin Exp Metastasis 38(1):1–10. doi: https://doi.org/10.1007/s10585-020-10063-x
11. Ricotti F, Giuliani K, Cataldi I, Campanati A, Ganzetti G, Ricotti G, Offidani A (2014) Electrochemotherapy: an effective
local treatment of cutaneous and subcutaneous melanoma metastases. Dermatol Ther 27(3):148–152. doi: https://doi.org/10.1111/dth.12098

12. Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, Chiariom-Sileni V, Rossi CR (2012) Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 99(6):821–830. doi: https://doi.org/10.1002/bjs.8749

13. PROSPERO database. https://www.crd.york.ac.uk/prospero/. Accessed 4 Jan 2021

14. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7)

15. Moga C, Guo B, Schopflocher D, Harstall C (2012) Development of a quality appraisal tool for case series studies using a modified Delphi technique. Edmonton: Institute of Health Economics; http://www.ihe.ca/advanced-search/development-of-a-quality-appraisal-tool-for-case-series-studies-using-a-modified-delphi-technique. Accessed 13 Sept 2021

16. Rudolf Z, Stubac B, Cemazar M, Miklavcic D, Vodovnik L, Seda G et al (1995) Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radial Oenal 29:229–264

17. Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R (1996) Bleomycin-mediated electrochemotherapy of metastatic melanoma. AMA Arch Derm 132(11):1353–1357

18. Ro Is MP, Bachaud JM, Giraud P, Chevrau C, Roché H, Teissié J (2000) Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 10(5):468–474

19. Caracó C, Marone U, Simeone E, Grimaldi AM, Botti G, Del Giudice M, Ascieto PA, Moffillo N (2015) Electrochemotherapy in melanoma patients: a single institution experience. Melanoma. Manag 2(2):127–132

20. Moffillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli G, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Caracó C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascieto PA (2015) Assessing a novel immuno-oncology-based combination therapy: ipilimumab plus electrochemotherapy. Oncoimmunology 4(6):e1008842

21. Hribernik A, Cemazar M, Sersa G, Bosnjak M, Snoj M (2016) Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients. Radiol Oncol 16(1):21–27. https://doi.org/10.1515/raon-2015-0048

22. Hepp M, Eigenher TK, Kähler KC, Herbst RA, Göppner D, Gambichler T et al (2016) Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother 65(8):951–959. https://doi.org/10.1007/s00262-016-1856-z

23. Sersa G, Stubac B, Cemazar M, Miklavcic D, Rudolf Z (2000) Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 6(3):863–867

24. Sersa G, Stubac B, Cemazar M, Miklavcič D, Rudolf Z (2000) Electrochemotherapy with cisplatin: the systemic antitumor effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 10(4):381–385

25. Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T, McCarthy WH (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15(1):45–51

26. Gaudy C, Richard MA, Fochetti G, Bonerandi JJ, Grob J et al (2006) Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 10(3):115–121. https://doi.org/10.2310/7750.2006.00037

27. Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Risson M et al (2008) Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann of Surg Oncol 15(8):2215–2222

28. Kis E, Olań J, Ócsai H, Baltas E, Gyulai R, Kemény L et al (2011) Electrochemotherapy of cutaneous metastases of melanoma—a case series study and systematic review of the evidence. Dermatol Surg 37(6):816–824

29. Tomassini GM, Covarelli P, Tomassini MA, Corsi A, Bianchi L, Hansel K et al (2016) Electrochemotherapy with intravenous bleomycin for advanced non-melanoma skin cancers and for cutaneous and subcutaneous metastases from melanoma. G Ital Dermatol Venereol 151(5):499–506

30. Kunte C, Letulé V, Gehl J, Dahlstroem K, Curatolo P, Rotunno R, Muir T, Occhini A, Bertino G, Powell B, Saxinger W, Lechner G, Liew SH, Pritchard-Jones R, Rutkowsi P, Zdziechinski M, Mowatt D, Sykes AJ, Orlando A, Mitsala G, Rossi CR, Campana L, Brizio M, de Terlizzi F, Quaglino P, Odili J (2017) InspECT (the International Network for Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol 176(6):1475–85

31. Mir-Bonafé JM, Vilalta A, Alarçon I, Carrera C, Puig S, Malvehy J, Rull R, Bennassar A (2015) Electrochemotherapy in the treatment of melanoma skin metastases: a report on 31 cases. Actas Dermosifiliogr 106(4):285–291. doi: https://doi.org/10.1016/j.ad.2014.10.007

32. Aguado-Romero MJ, Benot-López S, Romero-Tabares A (2017) Electrochemotherapy for the treatment of unreatsectable locoregionally advanced cutaneous melanoma: a systematic review. Actas Dermosifiliogr 108(2):91–97

33. Clove AJP, de Terlizzi F, Bertino G, Curatolo P, Odili J, Campana LG, Kunte C, Muir T, Brizio M, Sersa G, Pritchard Jones R, Moir G, Orlando A, Banerjee SM, Kis E, McCaul JA, Grischem EC, Matteucci P, Mowatt D, Bechara FG, Mascherini M, Lico V, Giorigone R, Seccia V, Schepler H, Pecoriar G, Mackenzie Ross AD, Bisas B, Gehl J (2020) Electrochemotherapy in the treatment of cutaneous malignancy: outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019). Eur J Cancer 138:30–40

34. Ursic K, Kos S, Kamensk U, Cemazar M, Scancar J, Bucek S, Krane S, Staresinic B, Sersa G (2018) Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma. Bioelectrochemistry 119:161–171

35. Roux S, Bernat C, Al-Sakere B, Ghringhelli F, Opolon P, Carpentier AF, Zitovil L, Mir LM, Robert C (2008) Tumor destruction using electrochemotherapy followed by Cpg oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 57(9):1291–1300

36. Theurich S, Rothschild SL, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, Thelen M, Schill C, Merki R, Schmid T, Keobere D, Zippelius A, Baues C, Mauch C, Tigges C, Kreuter A, Borggreve J, von Bergwelt-Baildon M, Schlaak M (2016) Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res 4(9):744–754

37. Campana LG, Peric B, Mascherini M, Sersa G, Kunte C, Kis E et al (2021) Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma: a comparative retrospective study from the InspECT and Slovenian Cancer Registry. Cancers (Basel) 13(17):25. doi: https://doi.org/10.3390/cancers13174289

38. Wilson MA, Schuchter LM (2016) Chemotherapy for Melanoma. Cancer Treat Res 167:209–229

39. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor–encoding, second-generation...
oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27(34):5763–5771.  https://doi.org/10.1200/JCO.2009.24.3675
40. Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ohrling K et al (2019) Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. J Immunother Cancer 7:145. https://doi.org/10.1186/s40425-019-0623-z
41. Louie RJ, Perez MC, Jajja MR, Sun J, Collichio F, Delman KA et al (2019) J Am Coll Surg 228:644–649. https://doi.org/10.1016/j.jamcollsurg.2018.12.027
42. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K et al (2013) Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann of Oncol 24(8):2174–2180
43. Maio M, Grob J-J, Aamdal S, Bondarenko I, Robert C, Thomas L et al (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33(10):1191–1196. https://doi.org/10.1200/JCO.2014.56.0018.33
44. Moreno-Ramírez D, Boada A, Ferrándiz L, Samaniego E, Carretero G, Nagore E, Redondo P, Ortiz-Romero P, Malvehy J, Botella-Estrada R (2018) Lymphnode dissection in patients with melanoma and sentinel lymph node metastasis: an updated, evidence-based decision algorithm. Actas Dermosifiliogr 109(5):390–398
45. Byers BA, Temple-Oberle CF, Hurdle V, McKinnon JG (2014) Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. J Surg Oncol 110(6):770–775
46. Petrelli F, Ghidini A, Simioni A, Campana LG (2021) Impact of electrochemotherapy in metastatic cutaneous melanoma: a contemporary systematic review and meta-analysis. Acta Oncol 10:1–12

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.